Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Weinstein

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Lancet (London, England)|September 10, 2016
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β<sub>2</sub>-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialEugene R Bleecker, J Mark FitzGerald, Pascal Chanez, et al.
The Journal of Allergy and Clinical Immunology|January 23, 2018
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthmaSteven F Weinstein, Rohit Katial, Shyamalie Jayawardena, et al.
Allergy and Asthma Proceedings|January 14, 2015
Recommendations for the pharmacologic management of allergic rhinitisFlavia C L Hoyte, Eli O Meltzer, Nancy K Ostrom, et al.
Open Forum Infectious Diseases|July 27, 2023
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)Michael G Ison, Debra F Weinstein, Marta Dobryanska, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Lancet (London, England)|September 10, 2016
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β<sub>2</sub>-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialEugene R Bleecker, J Mark FitzGerald, Pascal Chanez, et al.
The Journal of Allergy and Clinical Immunology|January 23, 2018
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthmaSteven F Weinstein, Rohit Katial, Shyamalie Jayawardena, et al.
Allergy and Asthma Proceedings|January 14, 2015
Recommendations for the pharmacologic management of allergic rhinitisFlavia C L Hoyte, Eli O Meltzer, Nancy K Ostrom, et al.
Open Forum Infectious Diseases|July 27, 2023
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)Michael G Ison, Debra F Weinstein, Marta Dobryanska, et al.
Pageof 11